CD47 was first identified in 1987 as an antigen that is missing in red blood cells of patients with Rhesus (Rh)-null hemolytic anemia (see the following reviews for CD47 source references unless otherwise cited: Rogers et al. 2012; Soto-Pantoja et al. 2015; Soto-Pantoja et al. 2013). Loss of CD47 is not the primary cause of this disease, but CD47 closely associates with the Rh complex on red blood cells. Independently, the same protein was identified as an antigen, OA3, that is overexpressed in ovarian carcinoma and as a protein that copurified with certain integrins and named integrin-associated protein (IAP). IAP and OA3 were shown in 1994 to be identical to CD47. CD47 is a type I integral membrane protein with an extracellular immunoglobulin variable (IgV)-like domain, five membrane-spanning segments, and a short alternatively spliced...
- Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25–50. https://doi.org/10.1146/annurev-immunol-032713-120142.CrossRefPubMedPubMedCentralGoogle Scholar
- Csányi G, Yao M, Rodríguez AI, Al Ghouleh I, Sharifi-Sanjani M, Frazziano G, Huang X, Kelley EE, Isenberg JS, Pagano PJ. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2966–73. https://doi.org/10.1161/ATVBAHA.112.300031.CrossRefPubMedPubMedCentralGoogle Scholar
- Kaur S, Roberts DD. Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling. Int J Biochem Cell Biol. 2016. https://doi.org/10.1016/j.biocel.2016.05.005, pii: S1357–2725(16)30111-X.
- Miller TW, Soto-Pantoja DR, Schwartz AL, Sipes JM, DeGraff WG, Ridnour LA, Wink DA, Roberts DD. CD47 receptor globally regulates metabolic pathways that control resistance to ionizing radiation. J Biol Chem. 2015;290:24858–74. https://doi.org/10.1074/jbc.M115.665752.CrossRefPubMedPubMedCentralGoogle Scholar
- Rogers NM, Yao M, Novelli EM, Thomson AW, Roberts DD, Isenberg JS. Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management. Am J Physiol Ren Physiol. 2012;303:F1117–25. https://doi.org/10.1152/ajprenal.00359.2012.CrossRefGoogle Scholar
- Soto-Pantoja DR, Kaur S, Miller TW, Isenberg JS, Roberts DD. Leukocyte surface antigen CD47. USCD Molecule Pages. 2013;2:1. https://doi.org/10.6072/H0.MP.A005186.01. http://www.signaling-gateway.org/molecule/query?afcsid=A005186. Accessed 29 July 2015.
- Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, Berzofsky JA, Roberts DD. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 2014;74:6771–83. https://doi.org/10.1158/0008-5472.CAN-14-0037-TCrossRefPubMedPubMedCentralGoogle Scholar
- Yao M, Roberts DD, Isenberg JS. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res. 2010. https://doi.org/10.1016/j.phrs.2010.10.014.
- Yao M, Rogers NM, Csányi G, Rodriguez AI, Ross MA, St Croix C, Knupp H, Novelli EM, Thomson AW, Pagano PJ, Isenberg JS. Thrombospondin-1 activation of signal-regulatory protein-α stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J Am Soc Nephrol. 2014;25:1171–86. https://doi.org/10.1681/ASN.2013040433.CrossRefPubMedPubMedCentralGoogle Scholar